Product info
For people living with cancer, time is precious. While medical advances mean new treatment options, treatment days can be long and tiring. Roche is working to improve the treatment experience for people with cancer. Roche’s Tecentriq® SC (atezolizumab) – a cancer immunotherapy used across a broad range of cancers – is the first subcutaneous (SC) PD-(L)1 inhibitor available to patients in the European Union. Clinical trial results show that Tecentriq SC can provide the established safety and efficacy of Tecentriq IV, with the potential of offering patients a faster, more convenient and flexible treatment option and to help free healthcare resources.
- Roche’s Tecentriq SC has been approved in all indications in which Tecentriq IV has been approved (ref 1-5)
- SC injection offers the potential for a faster, more convenient alternative to IV infusion and to save healthcare resources, and is preferred by cancer patients, nurses and physicians.(ref 1-5)
- The SC formulation of Tecentriq reduces treatment time by approximately 80%, with most injections taking between 4 and 8 minutes, compared 30-60 minutes for standard IV infusion.(Ref 6)
- 90% of healthcare professionals who were surveyed in our IMscin001 study agreed that the Tecentriq SC is easy to administer and 75% said it could save time for healthcare teams compared with IV.(Ref 6)
Product subject to medical prescription which may not be renewed (A)
Supporting materials
